Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 29885. Отображено 100.
12-01-2012 дата публикации

Differentiating cardiac- and diabetes mellitus-based causes of kidney damage

Номер: US20120009607A1
Автор: Andrea Horsch, Dietmar Zdunek, Georg Hess
Принадлежит: Roche Diagnostics Operations Inc

Disclosed is a method for differentiating in a subject suffering from kidney damage between kidney damage caused by (i) heart failure and/or (ii) diabetes mellitus type 1 or type 2 including the steps of: a) determining the amount of liver-type fatty acid binding protein (L-FABP) and the amount of kidney injury molecule 1 (KIM-1) in a urine-sample of a subject and forming the L-FABP/KIM-1 ratio; b) determining the amount of adiponectin in a urine-sample of said subject; and c) comparing the ratio determined in a) and the amount determined in b) with reference amounts, and establishing the predominant cause of the kidney damage. Also disclosed are a device and a kit for carrying out the method.

Подробнее
Номер записи: 1
02-02-2012 дата публикации

Whitefly Ecdysone Receptor Nucleic Acids, Polypeptides, and Uses Thereof

Номер: US20120028300A1
Автор: Dean Ervin Cress, Jianzhong Zhang, Subba Reddy Palli, Tarlochan Singh Dhadialla
Принадлежит: Intrexon Corp

The present invention relates to a novel isolated whitefly ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the whitefly ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate whitefly ecdysone receptor activity.

Подробнее
Номер записи: 2
23-02-2012 дата публикации

TNF-alpha Antagonists Containing IGFBP5

Номер: US20120046217A1
Автор: Jae-ho Huh, Jae-Ryoung Hwang, Je-Ho Lee
Принадлежит: Sungkyunkwan University Foundation For Corporate Collaboration

The present invention relates to: TNF-α antagonists containing IGFBP5 protein, variants thereof, or fragments thereof; and the use of the TNF-α antagonists. More specifically, the present invention relates to: a polynucleotide encoding the protein, variants thereof, or fragments thereof; a vector containing the polynucleotide; a transformant containing the vector; and a method for screening a therapeutic agent for TNF-α overexpression-related diseases by checking whether the mutual reaction thereof is facilitated after treating with candidates to the cell expressing the IGFBP5 protein, variants thereof, or fragments thereof, and the TNER1.

Подробнее
Номер записи: 3
01-03-2012 дата публикации

Methods of diagnosing cervical cancer

Номер: US20120052484A1
Автор: Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer, Michael P. Belmares, Peter S. Lu
Принадлежит: Individual

The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

Подробнее
Номер записи: 4
08-03-2012 дата публикации

Anti- integrin antibodies, compositions, methods and uses

Номер: US20120058128A1
Автор: Jill Giles-Komar, Linda Snyder, Marian T. Nakada, Mohit Trikha
Принадлежит: Janssen Biotech Inc

The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Подробнее
Номер записи: 5
15-03-2012 дата публикации

Psca: prostate stem cell antigen and uses thereof

Номер: US20120063999A1
Автор: Aya Jakobovitz, Douglas C. Saffran, Owen N. Witte, Robert E. Reiter
Принадлежит: Agensys Inc, UNIVERSITY OF CALIFORNIA

The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Подробнее
Номер записи: 6
15-03-2012 дата публикации

Il-17 homologous polypeptides and therapeutic uses thereof

Номер: US20120064073A1
Автор: Audrey Goddard, Austin L. Gurney, Colin K. Watanabe, Daniel G. Yansura, Daniel Tumas, Dorothy French, Ellen Fllvaroff, Hanzhong Li, J. Christopher Grimaldi, James Pan, Jian Chen, Kenneth J. Hillan, Melissa A. Starovasnik, Menno Van Lookeren, P. Mickey Williams, Paul J. Godowski, Richard Vandlen, Sarah G. Hymowitz, Sherman Fong, William I. Wood
Принадлежит: Individual

The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Подробнее
Номер записи: 7
15-03-2012 дата публикации

Predicting risk of major adverse cardiac events

Номер: US20120065897A1
Автор: Eugene R. Heyman, James V. Snider
Принадлежит: Critical Care Diagnostics Inc

Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.

Подробнее
Номер записи: 8
22-03-2012 дата публикации

Methods And Marker Combinations For Screening For Predisposition To Lung Cancer

Номер: US20120071334A1
Автор: Bhawani Singh, Eric L. Russell, Javier Ramirez, John C. Russell, Stephen Frost, Tracey Colpitts
Принадлежит: ABBOTT LABORATORIES

The present invention relates to rapid, sensitive methods for determining whether a subject has or is at risk of developing lung cancer based on certain combinations of biomarkers, or biomarkers and biometric parameters. The methods consist of: a) quantifying in a test sample obtained from a subject, the amount of two or more biomarkers in a panel, the panel comprising at least one antibody and at least one antigen: b) comparing the amount of each biomarker quantified in the panel to a predetermined cutoff for said biomarker and assigning a score for each biomarker based on said comparison: c) combining the assigned score for each biomarker quantified in step b to obtain a total score for said subject: d) comparing the total score in step c with a predetermined total score and e) determining whether said subject has a risk of lung cancer based on the comparison in step d.

Подробнее
Номер записи: 9
22-03-2012 дата публикации

Therapeutic application of isolated naturally-occuring soluble truncated forms of IL-23 receptor

Номер: US20120071422A1
Автор: Grant Gallagher, Jonathan Brazaitis, Raymond Yu
Принадлежит: Medical Diagnostic Laboratories LLC

The present invention relates to an isolated naturally-occurring soluble truncated IL-23Rα protein, which is a translated protein resulting from a mRNA splice variant of IL-23Rα. The soluble IL-23Rα proteins (e.g., Δ9 and Δ8,9) represents a novel soluble IL-23Rα protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that Δ9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23Rα protein. More importantly, the present invention provides an utility application of the Δ9 and Δ8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, Δ9 and Δ8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of Δ9 and Δ8,9 in treating a human patient inflicted with Crohn's disease.

Подробнее
Номер записи: 10
29-03-2012 дата публикации

Compartment-Specific Non-HLA Targets for Diagnosis and Prediction of Graft Outcome

Номер: US20120077689A1
Автор: Atul J. Butte, Minnie M. Sarwal
Принадлежит: Leland Stanford Junior University

Methods and composition are provided for diagnosing or predicting the status or the outcome of a graft transplant. In some embodiments, the presence or absence of one or more proteins recognizing a non-HLA/non ABO antigen is determined. The obtained result is then employed to diagnose or predict the status or outcome of the graft transplant. Also provided are compositions, systems and kits that find use in practicing the subject methods.

Подробнее
Номер записи: 11
26-04-2012 дата публикации

Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof

Номер: US20120101029A1
Автор: Asya Varshavsky, Boaz Kigel, Gera Neufeld, Ofra Kessler
Принадлежит: Rappaport Family Institute for Research in the Medical Sciences

A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.

Подробнее
Номер записи: 12
17-05-2012 дата публикации

Treatment of oncostatin m receptor beta mediated heart failure

Номер: US20120121579A1
Автор: Henning Warnecke, Jochen Pöling, Thomas Braun, Thomas Kubin, Wolfgang Rees
Принадлежит: Max Planck Gesellschaft zur Foerderung der Wissenschaften eV

The present invention relates to an inhibitor of the oncostatin M receptor β or an inhibitor of an activator of the oncostatin M receptor β for use in the treatment and/or prevention of heart failure. The present invention also relates to a method of treating and/or preventing heart failure comprising administering a pharmaceutically effective amount of an inhibitor of the oncostatin M receptor β or an inhibitor of an activator of the oncostatin M receptor β to a subject in need thereof. Further, the present invention also relates to methods of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of heart failure.

Подробнее
Номер записи: 13
17-05-2012 дата публикации

Anti-estrogen and immune modulator combinations for treating breast cancer

Номер: US20120121620A1
Автор: David A. Sirbasku
Принадлежит: Individual

Compositions for treating cancers of mucosal tissues including breast, prostate, ovary, colon are disclosed which include various combinations of new or conventional anti-estrogen compounds, aromatase inhibitors, immune modulators, immune inhibitors, immune inhibitor mimicking compounds and steroid or thyroid hormones. Methods of predicting susceptibility of a cancer of mucosal origin to treatment with a composition containing an immune inhibitor or an immune inhibitor mimicking compound are also disclosed. Preferred methods include identifying in a specimen of cancer cells the presence of a Poly-Ig (Fe) receptor or Poly-Ig-like (Fc) receptor capable of binding to an immune inhibitor or an immune inhibitor mimicking compound and of mediating immune inhibition of cancer cell growth.

Подробнее
Номер записи: 14
17-05-2012 дата публикации

Agents and Methods Related to Reducing Resistance to Apoptosis-Inducing Death Receptor Agonists

Номер: US20120122724A1
Автор: Robert P. Kimberly, TONG Zhou
Принадлежит: UAB RESEARCH FOUNDATION

Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of selectively inducing apoptosis in a target cell, treating a subject with cancer, autoimmune or inflammatory diseases, comprising administering compositions provided herein. Further provided are compositions comprising agents that modulate CARD containing proteins.

Подробнее
Номер записи: 15
24-05-2012 дата публикации

Diagnosis and treatment of autoimmune demyelinating diseases

Номер: US20120128698A1
Автор: Menno Van Lookeren Campagne
Принадлежит: F Hoffmann La Roche AG

The present invention concerns the diagnosis and treatment of autoimmune demyelinating diseases, such as multiple sclerosis (MS), by means of a CLM-I agonist.

Подробнее
Номер записи: 16
24-05-2012 дата публикации

Methods and compositions for diagnosing ankylosing spondylitis using biomarkers

Номер: US20120129185A1
Автор: Robert L. Wong, Walter P. Maksymowych
Принадлежит: Abbott Biotech Ltd Bermuda

The invention provides a method for determining the efficacy of a TNFα inhibitor, such as a TNFα antibody, or an antigen-binding portion thereof, for treating ankylosing spondylitis (AS), using a collagen degradation biomarker and/or a synovitis biomarker.

Подробнее
Номер записи: 17
24-05-2012 дата публикации

Detection and treatment of autoimmune disorders

Номер: US20120130350A1
Автор: Anne M. Stevens, Neelufar Mozaffarian
Принадлежит: Seattle Childrens Hospital

Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.

Подробнее
Номер записи: 18
14-06-2012 дата публикации

Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein b ratios

Номер: US20120149596A1
Автор: Joseph L. Witztum, Sotirios Tsimikas
Принадлежит: UNIVERSITY OF CALIFORNIA

The present invention relates to the analysis of oxidized phospholipids (OxPL) on apolipoprotein B-100 in patients at high risk or with documented coronary artery disease (CAD) or acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction or suspected of being at risk for ACS. Such methods are useful for diagnostic purposes and for monitoring the effects of dietary interventions or with drugs such as statins. More particularly, the present invention relates to methods for determining OxPL/apoB ratios as indices of atherosclerosis regression and plaque stability.

Подробнее
Номер записи: 19
21-06-2012 дата публикации

Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative Disorders

Номер: US20120156221A1
Автор: Alain Van Dorsselaer, Jose Alain Sahel, Ludivine Perrocheau, Thierry Leveillard
Принадлежит: Institut National de la Sante et de la Recherche Medicale INSERM

The invention relates to compounds which activate the BASIGIN signaling pathway, preferably agonists of BASIGIN, for the treatment of neurodegenerative disorders.

Подробнее
Номер записи: 20
21-06-2012 дата публикации

Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof

Номер: US20120156681A1
Автор: Ho-Kyung Chun, Woo Yong Lee, Yong Beom Cho
Принадлежит: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

The present invention relates to a composition for diagnosis of liver metastasis of colorectal cancer and the use thereof, and more particularly to a composition for diagnosis of liver metastasis of colorectal cancer, which comprises either a substance for measuring the mRNA level of CCL7 (Chemokine (C-C motif) ligand 7) gene or a substance for measuring the level of a protein which is encoded by the gene. According to the present invention, whether liver metastasis of colorectal cancer occurred can be diagnosed by measuring the mRNA expression level of the CCL7 gene or the expression level of the CCL7 protein, and the use of the composition comprising an inhibitor of CCL7 gene allows the treatment of colorectal cancer or the liver metastasis of colorectal cancer.

Подробнее
Номер записи: 21
28-06-2012 дата публикации

Test method on renal diseases

Номер: US20120164662A1
Автор: Akihiko Saito, Hiroyuki Kurosawa, Katsuhiko Asanuma, Masanori Hara, Shinya Ogasawara, Yasuhiko Tomino, Yoshiaki Hirayama
Принадлежит: Denka Seiken Co Ltd, Juntendo Educational Foundation, Niigata University NUC

Provided is a test method for the assessment of the necessity of renal biopsy in a subject to be tested, who is suspected of having a renal disease. Specifically provided are a test method for a renal disease, including using urinary podocalyxin and one or more additional markers in combination, and a test reagent for use in the test method and a test reagent kit for use in the test method. The present invention allows the discrimination of a poor prognosis group even for poor prognosis cases with no overt findings in a conventional test method, and thus allows the assessment of a renal disease, the assessment of the necessity of renal biopsy, prognostic prediction, and the like to be performed exactly.

Подробнее
Номер записи: 22
12-07-2012 дата публикации

Human cdr-grafted antibody and antibody fragment thereof

Номер: US20120177643A1
Автор: Akiko Shimizu, Emi Hosaka, Kazuyasu Nakamura, Kenya Shitara, Masamichi Koike
Принадлежит: Kyowa Hakko Kirin Co Ltd

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.

Подробнее
Номер записи: 23
19-07-2012 дата публикации

Methods for treating inflammation

Номер: US20120184616A9
Автор: Dakai Liu, Elazar Rabbani, James J. Donegan, Richard Jin, Riddhi Bhattacharyya, Wei Cheng, Xiaofeng Li, Yazhou Zhang
Принадлежит: Individual

The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.

Подробнее
Номер записи: 24
02-08-2012 дата публикации

Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators

Номер: US20120195889A1
Автор: Edwin A. Clark, Shirin K. Ford, Xin Huang
Принадлежит: Bristol Myers Squibb Co

EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.

Подробнее
Номер записи: 25
02-08-2012 дата публикации

Human domain antibodies against components of the human insulin-like growth factor (igf) system

Номер: US20120195897A1
Автор: Dimiter S. Dimitrov, Weizao Chen
Принадлежит: US Department of Health and Human Services

The invention provides antibodies or antibody fragments that bind to insulin-like growth factor (IGF) 1 receptor (IGF-1R) or IGF-2, as well as method of using the antibodies for inhibiting the IGF-mediated signaling pathway, inhibiting IGF-1R signaling, and treating cancer. The invention also provides a method of detecting the presence of IGF-1R or IGF-2 in a sample using the inventive antibodies and antibody fragments.

Подробнее
Номер записи: 26
02-08-2012 дата публикации

IAP BIR domain binding compounds

Номер: US20120195915A1
Автор: Alain Boudreault, Alain Laurent, James Jaquith, Patrick Bureau, Scott Jarvis
Принадлежит: Pharmascience Inc

Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R 1 , R 1a , R 100 , R 100a , R 2 , R 200 , W, B, and W 1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.

Подробнее
Номер записи: 27
09-08-2012 дата публикации

Drg11-responsive (dragon) gene family

Номер: US20120204280A1
Автор: Clifford J. Woolf, Tarek A. Samad
Принадлежит: General Hospital Corp

This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.

Подробнее
Номер записи: 28
23-08-2012 дата публикации

Diagnostic and Therapeutic Uses for B Cell Maturation Antigen

Номер: US20120213768A1
Автор: Gérard ZURAWSKI, Jacques F. Banchereau, Maria Virginia Pascual, Sangkon Oh
Принадлежит: BAYLOR RESEARCH INSTITUTE

Biomarkers and therapies against autoimmune diseases, including systemic lupus erythematosus (SLE) are described herein. The present invention is based on the discovery of B cell maturation antigen (BCMA) and BCMA variant expression on SLE monocytes that can be directly associated with disease activity. The findings of the present invention enable the design of monoclonal antibodies or recombinant proteins that can block BCMA and BCMA variants as well as BCMA-bound APRIL.

Подробнее
Номер записи: 29
23-08-2012 дата публикации

Detection of specific antigens in a population of antigens

Номер: US20120214176A1
Автор: Henry A. Graham, James P. Rowell, John G. Gorman
Принадлежит: Gorman John G, Graham Henry A, Rowell James P

Methods for detecting the presence or absence of, and for quantifying, one set of cells in a mixed cell population of at least two sets of cells especially Rh positive cells in a mixed population with Rh negative cells, as is found in a fetal maternal hemorrhage (FMH). The magnetic particles coated with anti-D antibodies are reacted with the Rh positive fetal cells in Rh negative maternal blood followed by a specific separation and quantifying technique. Gravitational forces or magnetic forces are used to move reacted magnetic particles to isolate, distinguish and quantify cells differentiated by antigenic composition. Rh positive cell volume is correlated to the volume of the original blood sample as an indication of the number of doses of RhIG needed to be administered to the mother to prevent subsequent Rh immunization.

Подробнее
Номер записи: 30
23-08-2012 дата публикации

Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2

Номер: US20120214737A1
Автор: Mark Marchionni
Принадлежит: Acorda Therapeutics Inc

The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.

Подробнее
Номер записи: 31
30-08-2012 дата публикации

Immunoregulation in cancer, chronic inflammatory and autoimmune diseases

Номер: US20120219973A1
Автор: Birgitta Clinchy, Leif Hakansson
Принадлежит: CANIMGUIDE THERAPEUTICS AB

The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.

Подробнее
Номер записи: 32
06-09-2012 дата публикации

Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression

Номер: US20120225015A1
Автор: Georgianna G. Gould, Mauris N. DeSilva, Stephen T. Schultz
Принадлежит: Desilva Mauris N, Gould Georgianna G, Schultz Stephen T

The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression.

Подробнее
Номер записи: 33
06-09-2012 дата публикации

Protein markers for detecting liver cancer and method for identifying the markers thereof

Номер: US20120225441A1
Автор: Sen-Yung Hsieh
Принадлежит: Chang Gung Medical Foundation Linkou Branch

The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer.

Подробнее
Номер записи: 34
13-09-2012 дата публикации

Marker associated with non-alcoholic steatohepatitis

Номер: US20120231471A1
Автор: Ayumi Sato, Takashi Yano, Tsuyoshi Harada, Yoko Wakabayashi
Принадлежит: Mochida Pharmaceutical Co Ltd

Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.

Подробнее
Номер записи: 35
13-09-2012 дата публикации

Compositions and Methods for Treatment of Eye Disorders

Номер: US20120232019A1
Автор: Johan Oslob, John Burnier, Kenneth Barr, Min Zhong, Thomas Gadek, Wang Shen
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

Подробнее
Номер записи: 36
20-09-2012 дата публикации

Compositions And Methods For Cell Based Retinal Therapies

Номер: US20120237473A1
Автор: Anton Kolomeyer, Ilene Sugino, Marco Zarbin
Принадлежит: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY

The invention relates to pharmaceutical compositions comprising trophic factors, methods to decrease the degeneration of a retina, methods of treating ocular degenerative diseases and methods to select cells for transplantation.

Подробнее
Номер записи: 37
11-10-2012 дата публикации

Treatment and Prevention of Dengue Virus Infections

Номер: US20120258079A1
Автор: Chelsea M. Byrd, Dennis E. Hruby, Dongcheng Dai, Robert Jordan
Принадлежит: Individual

Methods and pharmaceutical compositions for treating viral infections, by administering certain 2 -aryl-benzothiazole or 2 -heteroaryl-benzothiazole derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

Подробнее
Номер записи: 38
18-10-2012 дата публикации

Receptors of rspo2 and rspo3

Номер: US20120263730A1
Автор: Andrei Glinka, Bisei Okawara, Christof Niehrs
Принадлежит: Deutsches Krebsforschungszentrum DKFZ

The present invention relates to the finding that Syndecans (Sdc) are receptors of Rspondin-2 (Rspo2) and Rspondin-3 (Rspo3). Thus, the present invention relates to the identification of Rspo2, Rspo3 and/or Sdc activity modulators by determining if a test compound has the ability to modulate the binding of an Rspo2 and/or Rspo3 polypeptide to an Sdc polypeptide. Further, the invention refers to novel uses for antagonists of Rspo2 and/or Rspo3 in the treatment of Sdc-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders.

Подробнее
Номер записи: 39
18-10-2012 дата публикации

Lymphocyte analysis for monitoring the progression of immunodeficiency virus

Номер: US20120264109A1
Автор: Chiranjit Deka, Jui Ming LIN, Mary GOYETTE
Принадлежит: Idexx Laboratories Inc

The present disclosure describes a method of monitoring disease progression in a mammal positive for immunodeficiency virus which includes collecting blood cells from a mammal to obtain a first blood sample adding antibodies such as CD4 and CD8 to the first blood sample scanning the blood sample to produce a first multivariate dot plot which may be used to quantify at least CD4 + and CD8 + blood cell populations to produce a first ratio. The first multivariate dot plot may also be used to quantify a CD8αβ low subpopulation which may be used to calculate a second ratio. A third ratio is calculated of the second ratio to the first ratio and the result plotted on a graph as a first point. This process may be repeated to produce a second point for evaluating an extent of disease progression.

Подробнее
Номер записи: 40
18-10-2012 дата публикации

Simultaneous detection of mutational status and gene copy number

Номер: US20120264127A1
Автор: Edmundo David Del Valle, Fabien Gaire, Hiro Nitta, Shalini Singh
Принадлежит: Ventana Medical Systems Inc

The present invention provides compositions and methods for simultaneously detecting mutational status and gene copy number. In particular, the present invention provides simultaneous measurement of gene copy number and detection of the L858R and Exon 19 del mutations in a tissue sample.

Подробнее
Номер записи: 41
18-10-2012 дата публикации

Mhc peptide complexes and uses thereof in infectious diseases

Номер: US20120264161A1
Автор: Henrik Pedersen, Jørgen Schøller, Liselotte Brix
Принадлежит: Dako Denmark ApS

Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.

Подробнее
Номер записи: 42
18-10-2012 дата публикации

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Номер: US20120264629A1
Автор: Jeff Gray, Joseph Anderberg, Kevin Nakamura, Paul Mcpherson
Принадлежит: Astute Medical Inc

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a diagnostic and prognostic biomarker in renal injuries.

Подробнее
Номер записи: 43
25-10-2012 дата публикации

Methods of modulating the ox40 receptor to treat cancer

Номер: US20120269825A1
Автор: Tomoki Ito, Yong-Jun Liu
Принадлежит: University of Texas System

Numerous disease states, such as human allergic, autoimmune, and autoimmune diseases, and cancer, may be treated by targeting OX40/OX40L. OX40L inhibits the generation of Tr1 cells from naïve and memory CD4+ T cells. This unique function of OX40L is not shared by two other costimulatory TNF-family members, GITR-ligand and 4-1BB-ligand. It has been shown that signaling the OX40-receptor on human T cells by antibodies, small molecules, or the OX40L modulates the generation and function of IL-10 producing Foxp3 + Treg immunosuppressive T cells and blocks Foxp3 + Treg function. Further, provided are high throughput methods for identifying compounds that can inhibit the immunosuppressive function of IL-10 producing Tr1 cells.

Подробнее
Номер записи: 44
01-11-2012 дата публикации

Binding Partners for the Thyrotropin Receptor and Uses Thereof

Номер: US20120276117A1
Автор: Bernard Rees Smith, Jadwiga Furmaniak, Jane Sanders
Принадлежит: RSR Ltd

A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.

Подробнее
Номер записи: 45
01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells

Номер: US20120276155A1
Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering MHC Class I-restricted and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to generate tolerogenic immune responses against the antigen, such as the generation of antigen-specific CD8+ regulatory T cells.

Подробнее
Номер записи: 46
01-11-2012 дата публикации

Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use

Номер: US20120276156A1
Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising APC presentable transplant antigens and immunosuppressants that provide tolerogenic immune responses (e.g., a reduction in CD8+ T cell proliferation and/or activity) specific to the APC presentable transplant antigens.

Подробнее
Номер записи: 47
01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses

Номер: US20120276158A1
Автор: Christopher Fraser, Roberto A. MALDONADO, Takashi Kei Kishimoto
Принадлежит: Selecta Biosciences Inc

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class I-restricted and/or MHC Class II-restricted epitopes associated with undesired CD8+ T cell responses and immunosuppressants that provide tolerogenic immune responses against antigens that comprise the epitopes.

Подробнее
Номер записи: 48
01-11-2012 дата публикации

Tolerogenic synthetic nanocarriers

Номер: US20120276159A1
Автор: Christopher Fraser, Christopher J. ROY, Grayson B. Lipford, Roberto A. MALDONADO
Принадлежит: Selecta Biosciences Inc

This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

Подробнее
Номер записи: 49
01-11-2012 дата публикации

5.9 kDa PEPTIDE IMMUNOASSAY METHOD

Номер: US20120276562A1
Автор: Fumio Nomura, Iwao Kiyokawa, Kazuyuki Sogawa, Kenta Noda, Momoe Sato, Ryo Kojima, Toshihide Miura, Wataru Kikuchi
Принадлежит: Nitto Boseki Co Ltd

Disclosed is an immunoassay method whereby a 5.9 kDa peptide which results from the degradation of the α-E chain and α chain of human fibrinogens and which is used as a peptide marker for diagnosing hepatic disease can be specifically assayed in a biological sample containing contaminating peptides by bringing antibodies that recognize the N terminal of said peptide marker and antibodies that recognize the C terminal of said peptide marker into contact with said peptide marker, forming immune complexes of said peptide marker and the two antibodies, and immunoassaying the obtained immune complexes.

Подробнее
Номер записи: 50
22-11-2012 дата публикации

Dynamic Monitoring of Activation of Receptor Tyrosine Kinase (RTK) in Living Cells Using Real-Time Microelectronic Cell Sensing Technology

Номер: US20120295253A1
Автор: Josephine Atienza, Naichen Yu, XIAO Xu, Xiaobo Wang, Yama A. Abassi
Принадлежит: Acea Biosciences Inc

Methods for identifying a compound capable of interacting with a Receptor Tyrosine Kinase (RTK) including providing a device capable of measuring cell-substrate impedance, adding test cells expressing a RTK to the device, measuring first impedances, adding a compound to at least one compound well and adding a vehicle control at least one control well, measuring second impedances of the compound well and the control well, determining the change in the impedance for the compound well and the one control well, comparing the change in impedance between the compound well and the control well, and identifying the compound interacts with the RTK if the comparison demonstrates a significant difference between the change in impedance.

Подробнее
Номер записи: 51
06-12-2012 дата публикации

METHOD OF ANALYZING HUMAN sCD14-ST

Номер: US20120309025A1
Автор: Hiroyuki Yokoi, Yoshikazu Okamura
Принадлежит: Mochida Pharmaceutical Co Ltd

An analysis method capable of accurately measuring human sCD14-ST when using a whole blood sample is provided. In the analysis method, human sCD14-ST in a whole blood sample is analyzed within 6 hours of the collection of the sample.

Подробнее
Номер записи: 52
06-12-2012 дата публикации

Methods for diagnosis, prognosis and methods of treatment

Номер: US20120309029A1
Автор: Aileen C. Cohen, Helen L. Francis-Lang, Omar D. Perez, Santosh K. Putta, Wendy J. Fantl
Принадлежит: Nodality Inc

This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of cells present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. The physiological status of a cell can be determined by comparing the intracellular status of one or more activation elements (e.g. the phosphorylation status of a signaling molecule) in a cell (e.g. a cancer cell) to that of another cell (e.g. a normal cell). The physiological status of a cell can be further classified by adding one or more modulators (e.g. an inhibitor or activator) to the cell in question. In some embodiments, the invention is directed to methods of determining a phenotypic profile of a population of cells.

Подробнее
Номер записи: 53
13-12-2012 дата публикации

Sepsis test

Номер: US20120315653A1
Автор: Kenneth Alun Brown, Sion Marc Lewis
Принадлежит: KINGS COLLEGE LONDON

There is provided a method for determining whether a subject has a bacterial infection comprising: identifying an abnormal expression of one or more of CD49e, CD 14, CD11c, CD49f, and CD29 on leucocytes in a sample obtained from the subject; wherein an abnormal expression of CD49e, CD 14, CD11c, CD49f or CD29 is indicative of the subject having a bacterial infection.

Подробнее
Номер записи: 54
20-12-2012 дата публикации

Method of treating psychological disorders

Номер: US20120321609A1
Автор: Ana Magalhaes, Hymie Anisman, Stephen Ferguson
Принадлежит: Individual

A method of desensitizing 5-HT 2 R signaling in the mammal is provided. The method comprises one or more of: 1) inhibiting CRFR1 activation of 5-HT 2A R signaling by preventing trafficking of intracellular vesicles or blocking recycling of 5-HT 2A R to the cell surface; 2) blocking PDZ binding motifs in the carboxyl-terminal tail domains of at least one of CRFR1, 5-HT 2A R or 5-HT 2C R; or 3) blocking the interaction of a 5-HT 2 R or a CRFR1 with a PDZ-domain-containing protein selected from the group consisting of MAGI-1 PDZ1, MAGI-2 PDZ1, MAGI-3 PDZ1, PSD95 PDZ 1&2, PSD95 PDZ3, CAL PDZ, SAP97 PDZ 1&2, PTPN13 PDZ 4&5, PDZK2 PDZ1, MPP3 PDZ, ERBIN PDZ and MUPP1 PDZ 12.

Подробнее
Номер записи: 55
27-12-2012 дата публикации

Methods of identifying obm modulators

Номер: US20120329671A1
Автор: Akihiro Tomoyasu, Eisuke Tsuda, Fumie Kobayashi, Hisataka Yasuda, Kanji Higashio, Kazuki Yano, Ken Takahashi, Kyoji Yamaguchi, Masaaki Goto, Masahiko Kinosaki, Naohiro Washida, Nobuaki Nakagawa, Nobuyuki Shima, Tomonori Morinaga
Принадлежит: AMGEN INC

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Подробнее
Номер записи: 56
03-01-2013 дата публикации

Agents for treating disease

Номер: US20130004513A1
Автор: André ENGLING, Benjamin Daelken, Chantal Zuber, Christoph Bruecher, Christoph Uherek, Frank Osterroth, Gregor Schulz, Holger Wallmeier, Kirsten Völp, Niklas Czeloth
Принадлежит: Individual

Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof.

Подробнее
Номер записи: 57
03-01-2013 дата публикации

Arrays Of Biological Membranes And Methods And Use Thereof

Номер: US20130005611A1
Автор: Anthony G. Frutos, Joydeep Lahiri, Peter J. Kalal, Steven J. Jonas, YE Fang
Принадлежит: Individual

The present invention overcomes the problems and disadvantages associated with prior art arrays by providing an array comprising a plurality of biological membrane microspots associated with a surface of a substrate that can be produced, used and stored, not in an aqueous environment, but in an environment exposed to air under ambient or controlled humidities. Preferably, the biological membrane microspots comprise a membrane bound protein. Most preferably, the membrane bound protein is a G-protein coupled receptor, an ion channel, a receptor serine/threonine kinase or a receptor tyrosine kinase.

Подробнее
Номер записи: 58
10-01-2013 дата публикации

Diagnostic and Prognostic Markers for Cancer

Номер: US20130012409A1
Автор: Frank M., Lance Miller, Suzy V. Torti
Принадлежит: Wake Forest University Health Sciences

Compositions and methods useful for diagnosis and prognosis of cancer are provided.

Подробнее
Номер записи: 59
17-01-2013 дата публикации

THERAPEUTIC USE OF THE ß2m PROTEIN

Номер: US20130017212A1
Автор: Clovis Rakotoarivelo, Marcel Mersel
Принадлежит: BETA INNOV

The use of beta2-microglobulin (β2m) as active ingredient, in particular in pharmaceutical compositions intended for the treatment of autoimmune diseases.

Подробнее
Номер записи: 60
17-01-2013 дата публикации

COMBINATION OF sPLA2 TYPE IIA MASS AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT

Номер: US20130017557A1
Автор: Alain Tedgui, Joseph Witztum, Sotirios Tsimikas, Ziad Mallat
Принадлежит: BIO-SYNECTICS Inc, Institut National de la Sante et de la Recherche Medicale INSERM, JW Pharmaceutical Corp, UNIVERSITY OF CALIFORNIA

The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: —measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) sPLA2 type HA mass and b) oxidized phospholipids on apolipoprotein B-IOO particles (OxPL/apoB), —combining said measurements, the combined value of sPLA2 type HA mass and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.

Подробнее
Номер записи: 61
17-01-2013 дата публикации

Muteins of tear lipocalin and methods for obtaining the same

Номер: US20130017996A1
Автор: Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Ian Kimber, Kristian Jensen, Martin Huelsmeyer, Rebecca Dearman, Richard Jones, Steffen Schlehuber
Принадлежит: PIERIS AG

The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

Подробнее
Номер записи: 62
24-01-2013 дата публикации

Heteroaryl Derivatives as CFTR Modulators

Номер: US20130023538A1
Автор: Brian Bear, Jinglan Zhou, Mark Miller, Sara Hadida Ruah
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Подробнее
Номер записи: 63
14-02-2013 дата публикации

Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow

Номер: US20130039907A1
Автор: Christopher R. Bebbington, Geoffrey T. Yarranton, Mark Baer, Varghese Palath
Принадлежит: Kalobios Pharmaceuticals Inc

The invention provides diagnostic and therapeutic methods for the treatment of hematological proliferative disorders.

Подробнее
Номер записи: 64
28-02-2013 дата публикации

Kit for measuring the thrombin generation in a sample of a sample of a patient's blood or plasma

Номер: US20130052672A1
Автор: Brigitte Keil, Hans-Peter Schwarz, Katalin Varadi, Peter Turecek, Sylvia Peyrer-Heimstaett
Принадлежит: Baxter Healthcare SA, Baxter International Inc

The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and CaCl 2 . The invention also provides processes for preparing the reagents for the kit. The kit can be used in a method for measuring the thrombin generation in a sample, wherein it is possible to detect changes in thrombin generation kinetics, for example after administration of inhibitor bypassing agents to a patient who has developed inhibitors to an exogenous clotting factor such as Factor VIII.

Подробнее
Номер записи: 65
07-03-2013 дата публикации

Antibodies that bind ov064 and methods of use therefor

Номер: US20130058864A1
Автор: John S. Babcook, Ole Petter Veiby
Принадлежит: Millennium Pharmaceuticals Inc

Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.

Подробнее
Номер записи: 66
07-03-2013 дата публикации

Identification and Enrichment of Cell Subpopulations

Номер: US20130061340A1
Автор: Bob Y. LIU, Marianne Santaguida, Samuel A. Williams, Scott J. Dylla, Wade C. Anderson
Принадлежит: Stemcentrx inc

Markers useful for the identification, characterization and, optionally, the enrichment or isolation of tumorigenic cells or cell subpopulations are disclosed.

Подробнее
Номер записи: 67
14-03-2013 дата публикации

Use of thrombin mutants to inhibit the anticoagulation effect of thrombin inhibitors

Номер: US20130064807A1
Автор: Andras Gruber, Enrico Di Cera, Kenichi Tanaka, Stephen Raymond Hanson
Принадлежит: EMORY UNIVERSITY, Oregon Health Science University, Washington University in St Louis WUSTL

The present disclosure provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present disclosure include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent. In one embodiment, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered. The present disclosure further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay.

Подробнее
Номер записи: 68
14-03-2013 дата публикации

Compositions and methods for detecting autoantibodies

Номер: US20130065252A1
Автор: Jaekyung Kim, Paul D. Olivo, Yunsheng Li
Принадлежит: Quidel Corp

The invention provides compositions and methods for detecting thyroid hormone blocking immunoglobulin (TBI). The invention's methods are sensitive and specific for TBI, and may be used for the dual detection of both TBI and TSI. The invention's compositions and methods are useful for the diagnosis of diseases that are associated with the presence of TBI and/or TSI, for monitoring the progress of disease and/or treatment regimens, therapeutics, vaccines, etc., and for assisting clinicians in making treatment decisions.

Подробнее
Номер записи: 69
28-03-2013 дата публикации

Methods and kits for determining von willebrand factor activity in the absence of ristocetin and for determining the activity of adamts-13 protease

Номер: US20130078652A1
Автор: Harald Althaus, Juergen Patzke, Reinhard Schneppenheim, Tobias Obser
Принадлежит: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH

Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.

Подробнее
Номер записи: 70
25-04-2013 дата публикации

Tiki1 and Tiki2, Wnt Inhibitors

Номер: US20130101582A1
Автор: Bryan MacDonald, Chika Yokota, Xi He, Xinjun Zhang
Принадлежит: Childrens Medical Center Corp

This invention relates to Tiki1 and Tiki2 proteins and nucleic acids, cells expressing the same, and methods for identifying compounds that modulate Tiki1/2 activity for use in the treatment of osteoporosis or cellular proliferative disorders.

Подробнее
Номер записи: 71
02-05-2013 дата публикации

Detection and treatment of lrp4-associated neurotransmission disorders

Номер: US20130108616A1
Автор: Bin Zhang, Changyong Shen, Lin Mei, Wen-Cheng Xiong
Принадлежит: Individual

The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.

Подробнее
Номер записи: 72
02-05-2013 дата публикации

Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer

Номер: US20130109629A1
Автор: Antje Prasse, Gernot Zissel, Joachim Müller-Quernheim
Принадлежит: Universitaetsklinikum Freiburg

The present invention relates to an isolated soluble CCR6 receptor polypeptide capable of binding to CCL18 and/or CCL20 and to a method for quantifying the concentration of a soluble CCR6 receptor polypeptide in a liquid sample from a subject. The present invention also relates to a method for detecting and/or prognosticating an interstitial lung disease or a cancer in a subject by determining the level of a soluble CCR6 receptor polypeptide in a sample from said subject and further provides a pharmaceutical composition comprising a compound capable of inhibiting the activity and/or the expression of CCL18 or CCL20 for the treatment of said diseases. The present invention further relates to an isolated polypeptide capable of binding to and inhibiting the activity of the chemokine receptor CCR6 and to a method for identifying further inhibitors of CCR6 receptor activity. The present invention also relates to a method for detecting an interstitial lung disease or a cancer in a subject by determining the level of CCR6 gene expression in a sample from said subject and further provides pharmaceutical compositions comprising inhibitors of CCR6 receptor activity and/or expression for the treatment of said diseases.

Подробнее
Номер записи: 73
09-05-2013 дата публикации

Compositions comprising modified collagen and uses therefor

Номер: US20130116405A1
Автор: Allen Y. Wang, Hyeseung J. Lee, Jennifer H. Elisseeff, Michael Yu, Xiao Mo
Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides modified collagen and related therapeutic and diagnostic methods.

Подробнее
Номер записи: 74
16-05-2013 дата публикации

Anti-human alpha9 integrin antibody and use thereof

Номер: US20130122019A1
Автор: Shigeyuki Kon, Toshimitsu Uede
Принадлежит: Gene Techno Science Co Ltd

The present invention relates to an anti-human α9 integrin antibody. More particularly, the present invention relates to: a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human α9 integrin; a hybridoma cell that produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human α9 integrin antibody; a diagnostic agent comprising the human α9 integrin antibody; and a method for screening for a compound that inhibits the activity of human α9 integrin.

Подробнее
Номер записи: 75
06-06-2013 дата публикации

Anti-CD74 Immunoconjugates and Methods of Use

Номер: US20130142729A1
Автор: David M. Goldenberg, Hans J. Hansen, John C. Byrd
Принадлежит: Immunomedics Inc, Ohio State University

Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.

Подробнее
Номер записи: 76
27-06-2013 дата публикации

Noninvasive detection of meconium in amniotic fluid

Номер: US20130165816A1
Автор: Gideon Mor
Принадлежит: Individual

Meconium stained amniotic fluid can indicate intrauterine fetal distress. The invention provides a system and method for detecting meconium in released amniotic fluid in pregnant women, including a collection body such as a hygienic pad, having a meconium detector. This invention is designed to be employed mainly by a lay person at home; it also may provide possible etiologies for fetal distress.

Подробнее
Номер записи: 77
18-07-2013 дата публикации

Administering anti-placental growth factor antibodies

Номер: US20130183310A1
Автор: Desire Collen, Peter Carmeliet, Ruvo Menotti, Sandro De Falco
Принадлежит: Individual

The present invention relates to the field of pathological angiogenesis and arteriogenesis and, in particular, to a stress-induced phenotype in a transgenic mouse (PIGF −/− ) that does not produce Placental Growth Factor (PIGF) and that demonstrates an impaired vascular endothelial growth factor (VEGF)-dependent response. PIGF deficiency has a negative influence on diverse pathological processes of angiogenesis, arteriogenesis and vascular leakage comprising ischemic retinopathy, tumor formation, pulmonary hypertension, vascular leakage (edema formation) and inflammatory disorders. The invention thus relates to molecules that can inhibit the binding of PIGF to its receptor (VEGFR-1), such as monocloncal antibodies and tetrameric peptides, and to the use of these molecules to treat the above-mentioned pathological processes.

Подробнее
Номер записи: 78
18-07-2013 дата публикации

Antibodies that bind to OX40 and their uses

Номер: US20130183315A1
Автор: Antoine Attinger, Jonathan Albert Back, Rami Lissilaa, Samuel Hou, Stanislas Blein
Принадлежит: Glenmark Pharmaceuticals SA

The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

Подробнее
Номер записи: 79
18-07-2013 дата публикации

Methods relating to identification of susceptibility to liver injury

Номер: US20130183668A1
Автор: Derek Mann, Jelena Mann, Mujdat Zeybal
Принадлежит: Individual

The present invention relates to methods for identifying susceptibility of impaired hepatic wound healing in a patient, most particularly by identifying modifications of the of PPAR-γ and TGFβ1 genes. It further relates to stratifying populations of patients to determine susceptibility to impaired hepatic wound healing and direct appropriate healthcare resources. More specifically methods can be used to stratify liver disease patient populations to identify those most likely to progress to cirrhosis, or to identify the likelihood that a patient with liver disease will progress to having cirrhosis.

Подробнее
Номер записи: 80
01-08-2013 дата публикации

Methods and compositions for improving sleep and memory

Номер: US20130195763A1
Автор: Charles F. Landry, Jason R. Gerstner, Jerry C. Yin
Принадлежит: Individual

A method for determining whether a substance can increase the expression level of a fatty acid binding protein (FABP) in an animal. The method includes using a cell that includes an expression construct that comprises a FABP promoter operably linked to a polynucleotide sequence encoding a reporter molecule, wherein the cell is contacted with a candidate substance and then cultivating the cell under conditions conducive to expression of the reporter molecule. Increased expression of the construct in the presence of the candidate substance as compared to a control leads to improved sleep and long-term memory in the subject.

Подробнее
Номер записи: 81
08-08-2013 дата публикации

Mobilization of hematopoietic stem cells

Номер: US20130202553A1
Автор: Yi Zheng
Принадлежит: Cincinnati Childrens Hospital Medical Center

Methods, processes, uses, and pharmaceutical compositions are provided herein for mobilizing hematopoietic progenitor cells and/or cancer stem cells from bone marrow into peripheral blood, comprising the administration of an effective amount of an inhibitor of GTPases, such as a Cdc-42 specific inhibitor alone or in combination with one or more additional agents. Specifically, methods are disclosed for mobilizing hematopoietic stem cells into a subject's peripheral blood. In particular, embodiments of the method involve specific inhibition of the Cdc42 GTPase to increase the numbers of hematopoietic stem cells into a subject's peripheral blood of a subject.

Подробнее
Номер записи: 82
08-08-2013 дата публикации

BISPECIFIC SINGLE CHAIN Fv ANTIBODY MOLECULES AND METHODS OF USE THEREOF

Номер: US20130202603A1
Автор: Eva M. Horak, Gregory P. Adams, James D. Marks, Louis M. Weiner
Принадлежит: FOX CHASE CANCER CENTER, UNIVERSITY OF CALIFORNIA

Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.

Подробнее
Номер записи: 83
08-08-2013 дата публикации

Diagnostic reagents

Номер: US20130203087A1
Автор: Gareth Jones, Hans Vordermeier
Принадлежит: UK Secretary of State for Environment Food and Rural Affairs

There is provided a diagnostic reagent useful to determine whether an animal has a tuberculosis infection or has been exposed to a tuberculosis agent, for example a Mycobacterium . The reagent is useful to distinguish between such an animal and an animal which has been vaccinated against a tuberculosis infection.

Подробнее
Номер записи: 84
08-08-2013 дата публикации

Methods and means for diagnosing spondylarthritis using autoantibody markers

Номер: US20130203088A1
Автор: Niklas Thomas BAERLECKEN, Torsten Witte
Принадлежит: MEDIZINISCHE HOCHSCHULE HANNOVER

The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis. In particular, detection of the presence of autoantibodies against CD74 and/or IKBKB allows early diagnosis of Spa, in particular, AS and undifferentiated spondyloarthritis.

Подробнее
Номер записи: 85
15-08-2013 дата публикации

Methods and compositions for stimulating a felidae t1r receptor

Номер: US20130209625A1
Автор: Bruce Bryant, Joseph G. Brand
Принадлежит: MONELL CHEMICAL SENSES CENTER, Specialites Pet Food SAS

Provided herein are methods for stimulating the T1R1/T1R3 receptor comprising contacting the receptor with pyrophosphate and one or more amino acids. Also provided, is a Felidae food product comprising pyrophosphate and one or more amino acids. Methods for determining the pyrophosphate-augmented activity of a test compound on the T1R1/T1R3 receptor are also described, as well as methods for adjusting the food formulation for Felidae.

Подробнее
Номер записи: 86
15-08-2013 дата публикации

Egfr-related polypeptides and methods of use

Номер: US20130210004A1
Автор: Edward L. Chan, James Keller
Принадлежит: Research Foundation of State University of New York

Described herein are truncated EGF receptor polypeptides, nucleic acids encoding them, and methods of using them to help select a method of treatment for an EGFR-related cancer, to predict clinical outcome, and to detect micrometastases or minimal residual disease. High EGFR expression and phosphorylated EGFR predicts poor survival in head and neck cancer patients, but does not correlate with advanced stage disease. In our studies, we determined that clinical biological correlates are likely to be more accurate when different aspects of EGFR are evaluated in combination. We analyzed EGFR phosphorylation, expression and mutations in 60 primary head and neck tumors. We not only found that head and neck tumors with either truncated or activated EGFR tend to have higher tumor and nodal stage, but also discovered three EGFR truncations.

Подробнее
Номер записи: 87
15-08-2013 дата публикации

Complex phosphoprotein activation profiles

Номер: US20130210034A1
Автор: Charles Goolsby, David Hedley, James Jacobberger, James Marvin, Phillip Woost, Sue Chow, Vincent Shankey
Принадлежит: Beckman Coulter Inc

The present specification discloses methods for determining a phosphoprotein activation profile in hematopoietic cells, methods for detecting a signal transduction activation state in an individual having or suspected of having a disease or condition associated with activation of a signal transduction pathway, methods for detecting leukemia, and kits for determining a phosphoprotein activation profile in a sample containing hematopoietic cells.

Подробнее
Номер записи: 88
15-08-2013 дата публикации

Diagnostic method

Номер: US20130210040A1
Автор: Ian Sargent, Ingrid Granne, Jennifer Southcombe
Принадлежит: Oxford University Innovation Ltd

It has been demonstrated that the level of sST2 increases in pregnant females suffering from pre-eclampsia. Accordingly, the level of sST2 in a pregnant female can be used to assess risk of developing pre-eclampsia.

Подробнее
Номер записи: 89
22-08-2013 дата публикации

Selective Androgen Receptor Modulators

Номер: US20130217732A1
Автор: Chris P. Miller
Принадлежит: Individual

This invention provides compounds of formula I, pharmaceutical compositions comprising a compound of formula I and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds and intermediates useful in the preparation of same.

Подробнее
Номер записи: 90
29-08-2013 дата публикации

Modulation of NR2F6 and methods and uses thereof

Номер: US20130225425A1
Автор: Christine Victoria Ichim, Richard Alexander Wells
Принадлежит: Individual

The application provides methods of modulating NR2F6 in a cell or animal in need thereof by administering an effective amount of a NR2F6 modulator.

Подробнее
Номер записи: 91
05-09-2013 дата публикации

Diagnosis and treatment of brain tumors

Номер: US20130230453A1
Автор: Peter John Wookey, Sebastian Furness, Terrance Johns
Принадлежит: Welcome Receptor Antibodies Pty Ltd

The present invention relates to methods for the localisation, diagnosis, prognosis and/or prediction of therapeutic outcome of cancer, as well as methods for treating or preventing cancer. In particular, the present invention relates to methods for the localisation, diagnosis, prognosis and/or prediction of therapeutic outcome of brain tumors expressing calcitonin receptor, as well as the treatment and prevention of brain tumors by targeting calcitonin receptor expressing brain tumour cells.

Подробнее
Номер записи: 92
05-09-2013 дата публикации

Cellular blood markers for early diagnosis of als and for als progression

Номер: US20130230499A1
Автор: Ester Yoles, Hadas Schori, Michal Eisenbach-Schwartz
Принадлежит: Yeda Research and Development Co Ltd

The present invention provides methods for early diagnosis of amyotrophic lateral sclerosis (ALS) and for determining the efficacy of a treatment for ALS in an ALS patient, i.e., monitoring ALS progression, utilizing cellular blood markers; as well as kits for carrying out these methods.

Подробнее
Номер записи: 93
05-09-2013 дата публикации

Use of molecular markers for the preclinical profiling of inhibitors of enzymes having histone deacetylase activity

Номер: US20130231472A1
Автор: Alexander B. Maurer, Bernd Hentsch, Martin Goettlicher, Martin Golebiewski, Oliver H. Kraemer, Pier Giuseppe Pelicci, Ping Zhu, Saverio Minucci, Thorsten Heinzel
Принадлежит: Individual

The present invention relates to the use of molecular markers and related signaling mechanisms for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity. The invention also relates to the use of such markers as diagnostic and/or prognostic tools for the treatment of tumor patients with such inhibitors.

Подробнее
Номер записи: 94
17-10-2013 дата публикации

Screening Method for Candidate Agonist Compounds for Adiponectin Receptor I

Номер: US20130273567A1
Автор: Kazushige Touhara, Masato Iwabu, Miki Iwabu, Takashi Kadowaki, Toshimasa Yamauchi
Принадлежит: Individual

A method of screening for candidate compounds for adiponectin receptor 1 agonist including a step of bringing test compounds into contact with cells to determine whether they cause intracellular influx of extracellular calcium ions and selecting, from the test compounds, compounds causing the intracellular influx of extracellular calcium ions as the candidate compounds for adiponectin receptor 1 agonist.

Подробнее
Номер записи: 95
07-11-2013 дата публикации

PVRL4 (Nectin4) is a Receptor for Measles Virus

Номер: US20130295114A1
Автор: Christopher D. Richardson
Принадлежит: Individual

PVRL4 is a tumor marker that is highly expressed on the surfaces of many carcinomas. Disclosed herein are compositions and methods that provide impetus for using measles virus as an oncolytic agent against PVRL4+ carcinomas and use of PVRL4-binding agents to interfere with viral infection.

Подробнее
Номер записи: 96
14-11-2013 дата публикации

Method for manufacturing an analysis substrate, and use thereof for detecting toxins

Номер: US20130303405A1
Автор: Hoang-Oanh Nghiem, Jordi Molgo, Luis Botana, Natalia Vilarino, Romulo Araoz
Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Institut Pasteur de Lille, UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

The présent invention relates to a method for manufacturing an analysis device including torpédo membrane fragments immobilized at the surface thereof, to the resulting analysis device, and to the use of said device for detecting, purifying, and characterizing molécules acting on nicotinic acetylcholine receptors. The présent invention is useful in the field of monitoring seafood, monitoring neurotoxic phytoplankton for the shellfish industry, monitoring the quality of bathing waters along tourist beaches, the field of monitoring fresh water reserves, the field of médical research, the field of the biological analysis and characterization of molécules, e.g., non-radioactive assays of the movement of the ligand-receptor bond on an ELISA-type microplate, thereby enabling compétitive agonists and antagonists of targets to be detected, e.g., of highly sensitive receptors.

Подробнее
Номер записи: 97
14-11-2013 дата публикации

Use of modulators of CCR5 in the treatment of Cancer and cancer metastasis

Номер: US20130303512A1
Автор: Richard G. Pestell
Принадлежит: Individual

This disclosure is directed, in part, to a method of determining whether a subject having cancer is at risk for developing metastasis of the cancer. In one embodiment, the method comprises (a) obtaining a biological sample from the subject having cancer; (b) determining CCR5 expression level and/or expression level of at least one of CCR5 ligands in the biological sample; and (c) if the expression level of CCR5 and/or of at least one of CCR5 ligands determined in step (b) is increased compared to CCR5 expression level and/or expression level of at least one of CCR5 ligands in a control sample, then the subject is identified as likely at risk for developing metastasis of the cancer.

Подробнее
Номер записи: 98
21-11-2013 дата публикации

Hybridoma cell line for producing antibody for type ii collagen

Номер: US20130309694A1
Автор: Chi-Yen Shen, Chih-Hsin Hung, I-Fen Chen, Shih-Han Wang, Shyh-Ming Kuo
Принадлежит: I-SHOU UNIVERSITY

The present invention provides a hybridoma cell line (DSM ACC3145), wherein the hybridoma cell line produces an antibody which specifically binds to an amino acid sequence of type II collagen comprising: K-G-E-P-G-D-D-G-P-S-C (as set forth in SEQ ID NO. 1); and a method for detecting osteoarthritis, by identifying a presence of type II collagen in a urine sample through containing the urine sample with the said antibody.

Подробнее
Номер записи: 99
28-11-2013 дата публикации

Breast cancer diagnostics

Номер: US20130316374A1
Автор: Daniel Schramek, Georg Schett, Ian J. Jacobs, Josef Penninger, Martin Widschwendter, Usha Menon
Принадлежит: IMBA Institut fur Molekulare Biotechonologie GmbH

The present invention relates to methods and means for detecting cancer or of predicting a patient developing cancer or of determining the rate of progression of cancer in a patient suffering from cancer, comprising determining RANKL activity and/or the amount of OPG in a sample of said patient.

Подробнее
Номер записи: 100